Back to News
Market Impact: 0.2
First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer
Source: PRWeb
Healthcare & Biotech
Akeso said the first patient has been dosed in Phase III study COMPASSION-40/AK104-313, evaluating cadonilimab as monotherapy. The article excerpt provides no further details on the study indication, timing, or results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Merck’s remigromig meets non-inferiority goal in DME trial
- Bank of America is bullish on these top stocks ahead of earnings
- Big Tech is betting $700 billion on AI. Healthcare will decide whether the bet pays off
- Trump’s Medicaid cuts strip health coverage from some legal immigrants—including refugees and victims of human trafficking
- Taiz hospitals near collapse as Houthis tighten siege: Yemen government
- How de-extincting dire wolves and woolly mammoths may extend human life
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Automating Financial Model Updates: A Source-Controlled Workflow
- Weekly Update: Live Event Center, In-App Documents, and Faster Transcripts